Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. Until today this year the stock’s price performance recorded a decrease of -2.43%. However, over the last six months, the performance has been stronger by -0.88%. The price of AZN decreased -3.37% over the last 30 days. And in the last five days, it has fallen by -1.77%.
AstraZeneca PLC (AZN) stock is currently valued at $66.15. During the last session, the stock experienced a remarkable rise, reaching $67.86 after opening at $67.75. The stock briefly dropped to $66.485 before ultimately closing at $66.63.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
The market performance of AstraZeneca PLC’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $76.56 on 04/25/23, while the lowest value for the same duration was $52.65 on 09/26/22.
52-week price history of AZN Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. AstraZeneca PLC’s current trading price is -13.60% away from its 52-week high, while its distance from the 52-week low is 25.64%. The stock’s price range during this time has been between $52.65 and $76.56. The trading volume for the Healthcare sector company’s shares reached about 2.38 million for the day, which was lower than the average daily volume of 5.21 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
AstraZeneca PLC (AZN) has experienced a quarterly decline of -10.55% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 202.81B and boasts a workforce of 83500 employees.
AstraZeneca PLC: Analysts’ Ratings Unveiled
As of right now, 23 analysts are rating AstraZeneca PLC as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 70.70, with a change in price of -7.51. Similarly, AstraZeneca PLC recorded 4,733,130 in trading volume during the last 100 days, posting a change of -10.20%.
AZN’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for AZN stands at 0.80. Similarly, the long-term debt-to-equity ratio is also 0.67.
AZN Stock Stochastic Average
Today, AstraZeneca PLC’s raw stochastic average for the past 50 days stands at 19.21%, indicating a rise from the raw stochastic average of the last 20 days, which was 11.00%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 33.59% and 41.73% respectively.
